Single domain serum albumin binding protein
Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
1. A composition comprising a single domain serum albumin binding protein, comprising complementarity determining regions CDR1, CDR2, and CDR3, wherein
a. the amino acid sequence of CDR1 is as set forth in SEQ ID NO: 15;
b. the amino acid sequence of CDR2 is as set forth in SEQ ID NO: 22; and
c. the amino acid sequence of CDR3 is as set forth in SEQ ID NO: 24.
2. The single domain serum albumin binding protein of claim 1 , comprising the amino acid sequence set forth in SEQ ID NO. 27.
3. The composition of claim 1 , further comprising a linker.
4. The single domain serum albumin binding protein of claim 3 , wherein said linker has an amino acid as set forth in SEQ ID NO:28-37.
5. A nucleic acid encoding the single domain serum albumin binding protein of claim 1 .
6. A vector comprising the nucleic acid from claim 5 .
7. A host cell transformed with a vector of claim 6 .
8. A method of making a single domain serum albumin binding protein according to claim 1 comprising culturing the host cell of claim 7 under conditions allowing the expression of the serum albumin binding protein and recovering and purifying the produced protein from the culture.
9. The single domain serum albumin binding protein of claim 1 , wherein said protein binds to mouse serum albumin with a binding affinity (Kd) that is about 1.5 fold to about 20 fold weaker than the binding affinity (Kd) of said protein towards human and cynomolgus serum albumin.
10. The single domain serum albumin binding protein of claim 1 , wherein said protein binds to human serum albumin with a human Kd (hKd), to cynomolgus serum albumin with a cynomolgus Kd (cKd), and wherein ratio between the hKd and cKd (hKd: cKd) ranges from about 20:1 to about 1:2.
11. The single domain serum albumin binding protein of claim 1 , wherein said protein has an elimination half-time of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.
12. A method for extending the half-life of a polypeptide or protein by attaching the single domain serum albumin binding protein of claim 1 thereto.